# **Resource Summary Report**

Generated by NIF on May 16, 2025

## **POLYMUN Scientific**

RRID:SCR\_003926

Type: Tool

### **Proper Citation**

POLYMUN Scientific (RRID:SCR\_003926)

#### **Resource Information**

URL: http://www.polymun.at/

**Proper Citation:** POLYMUN Scientific (RRID:SCR\_003926)

**Description:** A private commercial company generating revenues by contract development and manufacturing biopharmaceuticals as well as creating liposomal formats of drugs for contract partners. These revenues are invested in the proprietary product pipeline and the further development of technology platforms. The R&D projects and technologies are open for co-development and licensing. Polymun operates in accordance with current GMP guidelines and holds an Austrian production license for pharmaceuticals (??63 Austrian Pharmaceutical Law) thus meeting the EU requirements for drug manufacturing. Its core competence is the development and manufacture of biopharmaceuticals, using both mammalian and microbial cell technology. A fine example are Polymun's broadly neutralizing HIV-1 antibodies produced in CHO cells. Other examples are recombinant human and porcine trypsin produced in yeast. Cell culture was also the basis for the development of a live attenuated influenza vaccine produced in Vero cells which led to the further investigation in genetically modified influenza viruses used as carrier for foreign epitopes (HIV, TB). Also the innovative liposome technology was initiated in order to optimize the formulation of the pharmacologically potent enzyme SOD, produced by Polymun in E. coli. Today, Polymun can apply this drug delivery platform to all kinds of pharmaceutically active ingredients. The industrial applicability in scale and price is a common focus throughout all projects and technologies.

**Abbreviations:** POLYMUN

Synonyms: Polymun Scientific Immunbiologische Forschung GmbH

**Resource Type:** commercial organization

**Keywords:** biopharmaceutical, liposomal formulation, drug manufacture, pharmaceutical,

liposome, drug

**Funding:** 

Resource Name: POLYMUN Scientific

Resource ID: SCR\_003926

Alternate IDs: nlx\_158293

Alternate URLs: http://www.polymun.com/

**Record Creation Time:** 20220129T080221+0000

**Record Last Update:** 20250420T014158+0000

### **Ratings and Alerts**

No rating or validation information has been found for POLYMUN Scientific.

No alerts have been found for POLYMUN Scientific.

#### Data and Source Information

Source: SciCrunch Registry

## **Usage and Citation Metrics**

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at <u>NIF</u>.

Joachim A, et al. (2016) Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. PloS one, 11(5), e0155702.

Pritchard LK, et al. (2015) Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. Cell reports, 11(10), 1604.